PURPOSE: To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). METHODS:Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. RESULTS: No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45). CONCLUSIONS: Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.
RCT Entities:
PURPOSE: To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT). METHODS: Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. RESULTS: No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45). CONCLUSIONS: Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.
Authors: Stephanie A S Staras; Sheila C Dollard; Kay W Radford; W Dana Flanders; Robert F Pass; Michael J Cannon Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: Siobhan Sutcliffe; Jonathan M Zenilman; Khalil G Ghanem; Rosemary A Jadack; Lori J Sokoll; Debra J Elliott; William G Nelson; Angelo M De Marzo; Stephen R Cole; William B Isaacs; Elizabeth A Platz Journal: J Urol Date: 2006-05 Impact factor: 7.450
Authors: Wen-Yi Huang; Richard Hayes; Ruth Pfeiffer; Raphael P Viscidi; Francis K Lee; Yun F Wang; Douglas Reding; Denise Whitby; John R Papp; Charles S Rabkin Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-09 Impact factor: 4.254
Authors: Jan Hrbacek; Michael Urban; Eva Hamsikova; Ruth Tachezy; Vaclav Eis; Marek Brabec; Jiri Heracek Journal: BMC Cancer Date: 2011-02-03 Impact factor: 4.430
Authors: J Bergh; I Marklund; C Gustavsson; F Wiklund; H Grönberg; A Allard; O Alexeyev; F Elgh Journal: Br J Cancer Date: 2006-11-21 Impact factor: 7.640
Authors: Siobhan Sutcliffe; Cathee Till; Frank J Jenkins; Charlotte A Gaydos; Phyllis J Goodman; Ashraful M Hoque; Ann W Hsing; Ian M Thompson; William G Nelson; Angelo M De Marzo; Elizabeth A Platz Journal: Cancer Causes Control Date: 2014-10-31 Impact factor: 2.506
Authors: Heather H Nelson; Emma Contestabile; DeVon Hunter-Schlichting; Devin Koestler; Michael Pawlita; Tim Waterboer; Brock C Christensen; Curtis L Petersen; Jeffrey S Miller; Karl T Kelsey Journal: Carcinogenesis Date: 2022-06-04 Impact factor: 4.741